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noncalciﬁed nodules 44 mm considered to be false positives
or malignant lesions. The prevalence of these nodules
44 mm ranges from 25% in the National Lung Cancer Screen-
ing Trial to 50% in the New York urban area studied by the
NYU Lung Cancer Biomarker Center [1]. Biomarkers for the
early detection of lung cancer have been a research priority
for the National Cancer Institute since the formation of the
Early Detection Research Network (EDRN) in 2000. This net-
work has funded a series of biomarker discovery laboratory
grants, and clinical validation centers for collecting human
samples. The EDRN has been organized by organ site, e.g.
lung, breast and women’s cancers, prostate, and gastrointest-
inal cancers. Workshops and executive committee meetings
allow the Principal Investigators and researchers interested
in biomarker discovery and testing to meet on a regular basis
and develop collaborations. For lung cancer, there are a
variety of tissues and samples that can be used with blood
being one of the most accessible for serum, plasma, and RNA;
urine; exhaled breath; sputum; brushings from buccal cavity,
nasal epithelium, and bronchial epithelium [2–5]. Second,
most assays take advantage of the ‘omics revolution and
high-throughput technologies’. Third, biostatistical analyses
and bioinformatics programs are necessary for data inter-
pretation. Lastly, study design is critical beginning with pilot
studies to small case: control studies, to larger sample sizes,
to multi-site epidemiological studies to prospective cohorts
and validation studies.
Serum or plasma proteins can be assayed with proteomics
platforms using various forms of mass spectrometry; more
recently, multiple reaction monitoring (MRM) has identiﬁed
the mass/charge peaks for speciﬁc proteins that can then be
quantiﬁed with differences between cancer and control
determined. Integrated Diagnostics has developed a panel
of plasma proteins to differentiate malignant from benign
nodules in the indeterminate range 8–30 mm in size. Out of
371 proteins identiﬁed from lung cancer tissue, cell lines, and
the literature, they developed a proﬁle of 13 proteins that
could accurately separate lung cancer cases from controls [6].
Another biotechnology company, SomaLogic, developed
nucleic acid aptamers that could bind speciﬁc proteins with
high avidity [7]. They have developed more than 1200 apta-
mers for various serum proteins and have a high-throughput.1016/j.resinv.2014.06.002
he Japanese Respiratory Society. Published by Elseplatform to perform a million or more reactions in a week. In
a case: control study with samples from four sites, they
identiﬁed a panel of 12 proteins that could separate lung
cancer from smoker controls with 88% accuracy and with an
area under the curve of 0.91. Half of the proteins were
increased and half were decreased. The presence of a benign
nodule or emphysema did not affect the ﬁndings. Interest-
ingly, they were related to cancer pathways in some regard, e.
g. cell growth or metabolism, invasion, inﬂammation, oxida-
tive stress, or anti-apoptosis. They were able to separate
proteins involved in acute phase reactions to compensate for
differences in blood draws and processing. Variant proteins
may be a marker for non-small cell lung cancer detected by
immunoblot [8]. A single protein has been utilized to follow
lung nodules over time as they are followed to determine
their growth rate. The rate of velocity of increase of osteo-
pontin correlated with lung cancer versus benign nodule
status [9]. We have found that screen detected lung cancers
separate into three somewhat equal groups: prevalent can-
cers detected on initial screen, incident lung cancers appear-
ing between periodic CT-screens, and indolent lung cancers
that grow very slowly and after ﬁve or more years of follow-
up, are still stage I adenocarcinomas upon pathologic evalua-
tion of surgical resections [1]. The dilemma of small, slow-
growing indolent tumors could well use a blood biomarker to
identify malignant nodules. Another approach is to utilize
Affymetrix micro-arrays for gene expression (transcrip-
tomics). Special tubes called PaxGene tubes can be used to
preserve RNA at 80 1C and facilitate separation of peripheral
blood mononuclear cells. Showe and colleagues were able to
identify a 29-gene signature capable of separating lung cancer
from smoker controls [10]. Furthermore, they identiﬁed
microRNAs that inﬂuenced these genes, and categorized
pathways into immune response, and cancer signaling path-
ways. Following surgical resection, the gene signature dis-
appeared demonstrating the speciﬁcity of the ﬁndings [11].
Since lung cancer represents aberrant cellular functions and
abnormal or changed proteins are secreted, the immune
system reacts and auto-antibodies are common. Early studies
evaluated autoantibodies against proteins related to cancer
such as p53, but panels to cell cycle proteins, apoptosis-related
proteins, oncogene products, invasion and signaling pathways
have been productive. We previously reported that a panel ofvier B.V. Open access under CC BY-NC-ND license.
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could distinguish lung cancer sera from smokers, and non-
smoker controls with a sensitivity of 81% and speciﬁcity
of 97% [12]. Auto-antibodies against glycan structures may
also be detected by high-throughput assays with 400 glycan
structures printed on glass slides for a high-throughput assay.
Glycan node structures or abnormal amounts of glycans can be
detected by mass spectrometry.
Abnormal methylation of promoters of tumor suppressor
genes and other key cancer genes may silence them causing
loss of function [13]. Cancer is characterized by global hypo-
methylation so hypermethylation of promoters is an unusual
cancer-related abnormality that can be detected by bisulﬁte
treatment and methylation-speciﬁc polymerase chain reaction
(PCR) with primers speciﬁc for the promoter region. Once again,
grouping a panel of genes for methylation-speciﬁc PCR pro-
duces a biomarker with greater accuracy.
Noncoding RNAs such as microRNAs that are short 19–22
circulating RNAs in plasma exosomes can be detected with
PCR and are mostly down-regulated in cancer [14]. There are
panels of microRNAs that correlate with biomarkers for lung
cancer with high accuracy [15].
The future of blood biomarkers is validation. Large surveys
of noncalciﬁed nodules in the range of 8–30 mm are needed
with low-dose CT scans for biomarker correlation to deter-
mine if the nodule is malignant or benign.
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